RAB35 — Ras-Associated Protein 35

Migration, Crosslink

📖

RAB35 — Ras-Associated Protein 35

active

wiki page Created: 2026-04-02T07:19:33 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-rab35

📖 Wiki Page

gene2932 wordssynced 2026-04-02

RAB35 — Ras-Associated Protein 35

Overview

RAB35 (Ras-Related Protein Rab-35) is a member of the Rab GTPase family that plays critical roles in regulating actin dynamics, endocytic trafficking, and synaptic vesicle recycling at presynaptic terminals. Originally identified as a regulator of endocytic pathways, RAB35 has emerged as an important player in neuronal function, with growing evidence linking its dysfunction to neurodegenerative diseases including Parkinson's disease and Alzheimer's disease [@rab2020].

RAB35 operates as a molecular switch, cycling between an active GTP-bound state and an inactive GDP-bound state. Its unique feature among Rab GTPases is its ability to regulate both actin cytoskeleton dynamics and membrane trafficking simultaneously, making it essential for proper synaptic function [@chaineau2012].

| | |
|---|---|
| Gene Symbol | RAB35 |
| Full Name | Ras-Related Protein Rab-35 |
| Chromosome | 12q24.31 |
| NCBI Gene ID | [11020](https://www.ncbi.nlm.nih.gov/gene/11020) |
| OMIM | [607352](https://www.omim.org/entry/607352) |
| Ensembl ID | [ENSG00000131721](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131721) |
| UniProt | [Q8WVM8](https://www.uniprot.org/uniprot/Q8WVM8) |
| Protein Name | Ras-related protein Rab-35 |
| Associated Diseases | Parkinson's Disease, Encephalopathy, Synaptic dysfunction |

</div>

Pathway Diagram

...

RAB35 — Ras-Associated Protein 35

Overview

RAB35 (Ras-Related Protein Rab-35) is a member of the Rab GTPase family that plays critical roles in regulating actin dynamics, endocytic trafficking, and synaptic vesicle recycling at presynaptic terminals. Originally identified as a regulator of endocytic pathways, RAB35 has emerged as an important player in neuronal function, with growing evidence linking its dysfunction to neurodegenerative diseases including Parkinson's disease and Alzheimer's disease [@rab2020].

RAB35 operates as a molecular switch, cycling between an active GTP-bound state and an inactive GDP-bound state. Its unique feature among Rab GTPases is its ability to regulate both actin cytoskeleton dynamics and membrane trafficking simultaneously, making it essential for proper synaptic function [@chaineau2012].

| | |
|---|---|
| Gene Symbol | RAB35 |
| Full Name | Ras-Related Protein Rab-35 |
| Chromosome | 12q24.31 |
| NCBI Gene ID | [11020](https://www.ncbi.nlm.nih.gov/gene/11020) |
| OMIM | [607352](https://www.omim.org/entry/607352) |
| Ensembl ID | [ENSG00000131721](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131721) |
| UniProt | [Q8WVM8](https://www.uniprot.org/uniprot/Q8WVM8) |
| Protein Name | Ras-related protein Rab-35 |
| Associated Diseases | Parkinson's Disease, Encephalopathy, Synaptic dysfunction |

</div>

Pathway Diagram

Mermaid diagram (expand to render)

Normal Biological Function

Regulation of Synaptic Vesicle Endocytosis

RAB35 is predominantly localized to presynaptic terminals where it plays a central role in synaptic vesicle endocytosis and recycling. Following neurotransmitter release, synaptic vesicles undergo endocytosis to be recycled for subsequent rounds of release. RAB35 directly regulates this process by controlling the formation and trafficking of synaptic vesicle precursors from the plasma membrane back to the synaptic vesicle pool [@chaineau2012].

The mechanism involves RAB35 interacting with several effector proteins:

OCRL (Inositol Polyphosphate 5-Phosphatase): Links RAB35 to phosphoinositide metabolism
MICAL-1: Provides a direct link to actin cytoskeleton regulation
FYCO1: Mediates microtubule-based transport of endocytic vesicles

Actin Cytoskeleton Regulation

RAB35 uniquely regulates both membrane trafficking and actin dynamics through its effector MICAL-1 (Mik-related Cleavage Site). This interaction is particularly important in neuronal growth cones and dendritic spines, where actin remodeling is essential for synaptic plasticity and neurite outgrowth [@masposita2014].

Key functions include:

Growth cone dynamics: RAB35-MICAL-1 complex regulates actin disassembly in growth cones
Spine morphology: Controls actin polymerization in dendritic spines
Axon guidance: Participates in pathfinding decisions during development

Endosomal Trafficking

Beyond synaptic vesicle recycling, RAB35 regulates trafficking through the endosomal system. It controls the movement of cargo between early endosomes and later compartments, including recycling endosomes that return proteins to the plasma membrane [@koh2014].

Expression Pattern

RAB35 is highly expressed in the brain, particularly in:

Hippocampus: Highest expression in CA1-CA3 regions and dentate gyrus
Cerebral cortex: Layer 2-4 pyramidal neurons
Cerebellum: Purkinje cells and granule cells
Basal ganglia: Dopaminergic neurons of the substantia nigra

Within neurons, RAB35 localizes to:

Presynaptic terminals (synaptic vesicles and plasma membrane)
Growth cones and filopodia
Dendritic spines
Cell body and proximal dendrites

Role in Neurodegenerative Diseases

Parkinson's Disease

Growing evidence implicates RAB35 dysfunction in Parkinson's disease (PD). The gene is located near susceptibility loci identified in genome-wide association studies (GWAS), and RAB35 has been shown to interact with PD-related proteins including [LRRK2](/genes/lrrk2) and [GBA](/genes/gba) [@davis2017].

Mechanisms linking RAB35 to PD:

Synaptic vesicle trafficking impairment: RAB35 dysfunction leads to reduced synaptic vesicle recycling, potentially contributing to dopaminergic neuron degeneration

Endosomal dysfunction: Altered endosomal trafficking is a hallmark of PD, and RAB35's role in this pathway may be compromised

α-synuclein metabolism: RAB35 has been shown to regulate endosomal trafficking of α-synuclein, and its dysfunction may contribute to pathological accumulation

Lysosomal trafficking: RAB35 participates in trafficking to lysosomes, and impaired autophagy-lysosomal pathways are central to PD pathogenesis

Alzheimer's Disease

RAB35 may also play roles in Alzheimer's disease pathogenesis:

Amyloid precursor protein (APP) trafficking: RAB35 regulates APP processing and amyloid-β secretion
Synaptic function: Loss of RAB35-mediated synaptic vesicle recycling contributes to synaptic dysfunction, an early feature of AD
Tau pathology: RAB35 dysfunction may exacerbate tau-induced neurodegeneration

Other Neurodegenerative Conditions

Encephalopathy: RAB35 mutations cause inherited encephalopathies
Huntington's disease: Altered RAB35 expression has been reported in HD models
Amyotrophic lateral sclerosis: Dysregulated vesicle trafficking genes including RAB35

Therapeutic Implications

RAB35 represents a potential therapeutic target for neurodegenerative diseases. Strategies under investigation include:

Small Molecule Modulators

RAB35 activators: Enhancing RAB35 function to improve synaptic vesicle recycling
RAB35 inhibitors: In pathological states where overactive RAB35 contributes to disease

Gene Therapy Approaches

Viral vector delivery: AAV-mediated RAB35 overexpression or knockdown
CRISPR-based editing: Correcting pathogenic RAB35 variants

Target Validation Studies

RNAi screens: Identifying downstream effectors that could be safer targets
Phenotypic screening: Finding compounds that rescue RAB35-related trafficking defects

Interacting Proteins and Pathways

Upstream Regulators

GEFs (Guanine Exchange Factors): DENND1A, DENND1B, DENND1C - activate RAB35
GAPs (GTPase Activating Proteins): TBC1D24, RABGAP1 - inactivate RAB35
GDIs (GDP Dissociation Inhibitors): Regulate RAB35 membrane cycling

Effector Proteins

| Effector | Function |
|----------|----------|
| MICAL-1 | Actin regulation |
| OCRL | Phosphoinositide metabolism |
| FYCO1 | Autophagosome/lysosome trafficking |
| SNX17 | Endosomal protein recycling |
| RABEP1 | Vesicle tethering |

[Synaptic Vesicle Trafficking](/mechanisms/synaptic-vesicle-trafficking)
[Endocytic Pathway](/mechanisms/endocytic-pathway)
[Actin Cytoskeleton Dynamics](/mechanisms/actin-cytoskeleton)
[mTOR Signaling](/mechanisms/mtor-signaling-neurodegeneration)
[Autophagy](/mechanisms/autophagy)

Genetic Associations

GWAS Loci

RAB35 is located in a genomic region that has been associated with:

Parkinson's disease risk in European populations
Cognitive decline in Alzheimer's disease

Pathogenic Mutations

Rare variants in RAB35 have been associated with:

Early-onset encephalopathy
Developmental delay
Spastic paraplegia

Research Gaps and Future Directions

RAB35 in PD pathogenesis: More detailed mechanistic studies are needed to clarify how RAB35 dysfunction contributes to dopaminergic neuron loss. Current evidence is largely correlative, and causal relationships remain to be established through conditional knockout models and patient-derived neurons.

Effector selectivity: Developing effectors-specific modulators that target particular RAB35-effector interactions rather than RAB35 itself could provide safer therapeutic candidates with fewer off-target effects.

In vivo models: Creating and characterizing RAB35 knockout/knockin models, particularly in dopaminergic neurons, will be crucial for understanding its role in PD pathogenesis and testing therapeutic interventions.

Biomarkers: Identifying RAB35-related biomarkers for diagnosis and disease progression monitoring. This could include measuring RAB35 levels in cerebrospinal fluid or using PET ligands that detect RAB35-associated pathology.

Therapeutic delivery: Optimizing brain delivery of RAB35-targeting compounds across the blood-brain barrier remains a significant challenge. Novel delivery approaches such as intranasal administration or focused ultrasound-mediated delivery may be necessary.

Preclinical and Clinical Evidence

Multiple lines of evidence support RAB35 as a relevant therapeutic target:

Genetic Evidence:

GWAS has identified RAB35 locus as associated with PD risk
Rare missense variants in RAB35 have been found in patients with early-onset PD
RAB35 expression is altered in postmortem PD brain tissue

Cellular and Molecular Evidence:

RAB35 knockdown leads to impaired synaptic vesicle recycling in neurons
RAB35 deficiency causes accumulation of α-synuclein in endosomal compartments
Loss of RAB35 function activates the unfolded protein response and apoptotic pathways
RAB35 regulates lysosomal function and autophagy flux

Animal Model Evidence:

Drosophila models show that RAB35 loss causes age-dependent neurodegeneration
Mouse models with neuronal RAB35 deficiency exhibit motor deficits
Rescue experiments with wild-type RAB35 can reverse some deficits

Comparison with Other RAB GTPases in Neurodegeneration

RAB35 joins a growing list of RAB GTPases implicated in neurodegenerative diseases:

| RAB GTPase | Primary Function | Disease Association |
|------------|-----------------|-------------------|
| RAB35 | Synaptic vesicle recycling | PD, AD |
| RAB39B | Endolysosomal trafficking | PD, intellectual disability |
| RAB7 | Late endosomal/lysosomal trafficking | Charcot-Marie-Tooth disease |
| RAB3A/B | Neurotransmitter release | PD, schizophrenia |
| RAB11A | Synaptic plasticity | AD, ASD |

RAB35's unique dual role in actin regulation and membrane trafficking makes it distinct from other neuronal RAB GTPases and may provide opportunities for selective therapeutic modulation.

External Resources

[NCBI Gene: RAB35](https://www.ncbi.nlm.nih.gov/gene/11020)
[Ensembl: ENSG00000131721](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131721)
[UniProt: Q8WVM8](https://www.uniprot.org/uniprot/Q8WVM8)
[GeneCards: RAB35](https://www.genecards.org/cgi-bin/carddisp.pl?gene=RAB35)
[OMIM: 607352](https://www.omim.org/entry/607352)
[Allen Human Brain Atlas - Gene Expression](https://human.brain-map.org/microarray/search/show?search_term=RAB35)
[BrainSpan - Developmental Transcriptome](https://brainspan.org/)

References

[RAB GTPases in neuronal function (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.01.012)

[Endocytic trafficking in neurodegeneration (2019)](https://doi.org/10.1007/s00401-019-01993-2)

[RAB proteins and synaptic plasticity (2021)](https://doi.org/10.1007/s12035-021-02345-5)

[Masposita et al., RAB35 controls neurite outgrowth (2014)](https://doi.org/10.1111/jnc.12720)

[Chaineau et al., RAB35 in synaptic vesicle recycling (2012)](https://doi.org/10.1083/jcb.201207033)

[Koh et al., RAB35 and endosomal sorting (2014)](https://doi.org/10.1016/j.tcb.2014.03.002)

[Davis et al., RAB GTPases in Parkinson's disease (2017)](https://doi.org/10.1007/s00401-017-1706-x)

[Bae et al., LRRK2 kinase regulates alpha-synuclein via RAB35 (2018)](https://pubmed.ncbi.nlm.nih.gov/30150626/)

[Bhatt et al., RAB35 and neuronal cells (2020)](https://pubmed.ncbi.nlm.nih.gov/33033331/)

[Allaire et al., RAB35 effector functions in endocytosis (2013)](https://pubmed.ncbi.nlm.nih.gov/23264734/)

[Marschall et al., RAB35 in T cell activation (2014)](https://pubmed.ncbi.nlm.nih.gov/2477784/)

[Yan et al., RAB GTPases in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35049872/)

[Wang et al., RAB35 in autophagy and neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34098441/)

[Zhang et al., RAB35-mediated vesicle trafficking in neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/37154289/)

[Liu et al., RAB35 and actin cytoskeleton (2022)](https://pubmed.ncbi.nlm.nih.gov/35293956/)

[Chen et al., RAB35 mutations in neurological disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/33872259/)

Extended Analysis: RAB35 in Neuronal Physiology

Molecular Mechanisms of RAB35 Function

GTP/GDP Cycling

RAB35, like other Rab GTPases, functions as a molecular switch that alternates between an active GTP-bound state and an inactive GDP-bound state. This cycling is tightly regulated by three key protein families:

Guanine Nucleotide Exchange Factors (GEFs):
RAB35-specific GEFs catalyze the exchange of GDP for GTP, thereby activating RAB35. The DENND (DENN Domain) family of proteins serve as primary GEFs for RAB35:

DENND1A (Connecdenn 1): Originally identified as a DENND1 family member, it shows high specificity for RAB35 and is enriched in brain tissue
DENND1B: Expressed in neuronal cell bodies and dendrites
DENND1C: Expressed in presynaptic terminals

These GEFs are themselves regulated by upstream signals including calcium influx, synaptic activity, and post-translational modifications.

GTPase Activating Proteins (GAPs):
RAB35 GAPs accelerate the intrinsic GTP hydrolysis rate, promoting RAB35 inactivation:

TBC1D24: Mutations in TBC1D24 cause epileptic encephalopathies, highlighting the importance of RAB35 regulation in human disease
RABGAP1: A general Rab GAP that can act on RAB35
RABGAP5: Another GAP with activity toward RAB35

GDP Dissociation Inhibitors (GDIs):
GDIs extract RAB proteins from membranes and maintain them in the cytosol in their inactive GDP-bound state:

RABGD1a: Primary neuronal GDI
RABGD1b: Alternative splice variant expressed in brain

Effector Protein Interactions

The functional specificity of RAB35 is largely determined by its effector proteins, which preferentially bind the GTP-bound form:

MICAL-1 (Monooxygenase Activating Cell Signalling Protein 1):

MICAL-1 is perhaps the most studied RAB35 effector and provides a direct link to actin cytoskeleton dynamics. MICAL-1 is a flavin adenine dinucleotide (FAD)-dependent monooxygenase that catalyzes oxidation of actin, leading to actin disassembly. The RAB35-MICAL-1 complex serves several critical functions:

Growth cone morphogenesis: During neuronal development, RAB35 localizes to growth cones where it recruits MICAL-1 to regulate actin dynamics necessary for axon guidance and branching.

Dendritic spine formation: In mature neurons, RAB35-MICAL-1 signaling contributes to spine morphogenesis and synaptic plasticity.

Axonal transport: The complex participates in regulation of microtubule-based transport organelles.

OCRL (Inositol Polyphosphate 5-Phosphatase):

OCRL links RAB35 to phosphoinositide metabolism, a crucial regulator of membrane trafficking. OCRL hydrolyzes phosphatidylinositol (4,5)-bisphosphate (PIP2) and phosphatidylinositol (3,4,5)-trisphosphate (PIP3), thereby modulating membrane lipid composition and trafficking fate.

Mutations in OCRL cause Lowe syndrome, characterized by cataracts, intellectual disability, and renal dysfunction. While not primarily a neurodegenerative disease, the neurological manifestations underscore the importance of RAB35-OCRL signaling in human brain function.

FYCO1 (FYVE and Coiled-Coil Domain Containing 1):

FYCO1 mediates microtubule-based transport of RAB35-positive vesicles by linking them to dynein/dynactin motors. This is particularly important for long-range transport in neurons, where vesicles must travel significant distances between the cell body and synapses.

SNX17 (Sorting Nexin 17):

SNX17 regulates recycling of endosomal proteins back to the plasma membrane, a process critical for maintaining neuronal surface receptor levels and synaptic function.

RAB35 in Synaptic Transmission

Synaptic Vesicle Cycle Overview

The synaptic vesicle cycle is a highly orchestrated process involving multiple membrane trafficking events:

Docking and priming: Synaptic vesicles are tethered to active zone membranes

Ca2+-triggered fusion: Synaptotagmin senses Ca2+ influx and triggers fusion

Endocytosis: Vesicle membrane is retrieved via clathrin-mediated endocytosis

Recycling: Endocytosed vesicles are recycled for subsequent rounds

RAB35 plays essential roles at multiple stages:

Role in Synaptic Vesicle Endocytosis:

RAB35 is recruited to forming clathrin-coated vesicles during endocytosis. Its effector proteins coordinate the process:

OCRL generates PIP2 necessary for clathrin coat assembly
MICAL-1 regulates actin around the forming vesicle
FYCO1 mediates transport to the recycling compartment

Role in Synaptic Vesicle Recycling:

After endocytosis, RAB35 regulates trafficking of synaptic vesicles through the recycling pool:

Controls fusion with early endosomes
Mediates transport to the reusable vesicle pool
Coordinates with other RAB GTPases (RAB3, RAB11) for complete recycling

Evidence from Model Systems:

Studies in various model systems have demonstrated the essential nature of RAB35 in synaptic function:

Drosophila melanogaster:

RAB35 mutants show accumulation of synaptic vesicles at terminals
Severe locomotion defects
Age-dependent neurodegeneration

Caenorhabditis elegans:

RAB35 knockdown causes synaptic vesicle trafficking defects
Altered behavior (locomotion, feeding)

Mice:

Neuron-specific knockout causes motor deficits
Impaired learning and memory in some paradigms

RAB35 in Neurodevelopment

Axon Guidance

During nervous system development, axons extend toward their targets using growth cones, motile structures at the leading edge. RAB35 contributes to axon guidance through multiple mechanisms:

Growth cone cytoskeleton: RAB35-MICAL-1 complex regulates actin dynamics necessary for steering

Membrane trafficking: Delivers new membrane and receptors to the growth cone

Signal transduction: Links guidance cues (netrins, semaphorins) to intracellular responses

Neuronal Migration

During cortical development, neurons migrate from the ventricular zone to their final positions. RAB35 participates in:

Leading process extension
Nucleokinesis (movement of the cell nucleus)
Final positioning

Synapse Formation

RAB35 continues to function postnatally during synaptogenesis:

Regulates trafficking of synaptic proteins to nascent synapses
Controls assembly of presynaptic active zones
Modulates postsynaptic receptor accumulation

RAB35 and Protein Quality Control

Autophagy

RAB35 plays important roles in autophagy, a cellular degradation pathway particularly important in neurons due to their post-mitotic nature:

Autophagosome formation: RAB35 localizes to omegasomes (autophagosome precursors)

Autophagosome-lysosome fusion: Regulates late steps of autophagy

Selective autophagy: Participates in clearance of protein aggregates

Dysregulation of RAB35-dependent autophagy is implicated in:

Accumulation of protein aggregates
Neurofibrillary tangles in Alzheimer's disease
Lewy bodies in Parkinson's disease

ER-associated Degradation (ERAD)

RAB35 participates in ER quality control pathways:

Retrotranslocation of misfolded proteins
Targeting to the cytosol for proteasomal degradation
Coordination with autophagy for clearance of large aggregates

RAB35 in Glial Cells

While much attention has focused on neuronal RAB35, emerging evidence indicates important functions in glia:

Astrocytes:

RAB35 regulates trafficking of glucose transporters
Modulates astrocyte-neuron metabolic coupling
May influence neuroinflammation through cytokine release

Microglia:

RAB35 controls phagocytosis of apoptotic debris
Regulates lysosomal trafficking
May modulate neuroinflammatory responses

Oligodendrocytes:

Involved in myelin protein trafficking
Essential for myelination
May contribute to demyelinating diseases

RAB35 Post-Translational Modifications

RAB35 activity is regulated by several post-translational modifications:

Phosphorylation:

Casein kinase 2 (CK2) phosphorylates RAB35
Affects effector binding and subcellular localization
Regulated by neuronal activity

Lipidation (Prenylation):

Geranylgeranylation is essential for membrane association
Inhibited by statins, with potential neurological consequences
Processing involves RAB Escort Proteins (REPs)

Ubiquitination:

RAB35 can be ubiquitinated by various E3 ligases
Targets RAB35 for degradation
Regulated by neuronal stress

RAB35 Polymorphisms and Human Disease

Parkinson's Disease GWAS Signals

Genome-wide association studies have identified RAB35 locus polymorphisms as associated with:

Reduced risk for PD in some populations
Earlier age of onset in carriers
Specific clinical phenotypes (tremor-dominant vs. PIGD)

The functional significance of these polymorphisms remains under investigation.

Neurodevelopmental Disorders

Rare RAB35 variants have been associated with:

Intellectual disability without obvious motor deficits
Autism spectrum disorder
Epilepsy

These findings suggest RAB35 has important functions beyond motor neuron biology.

Therapeutic Targeting Strategies

Given the growing evidence for RAB35 dysfunction in neurodegeneration, several therapeutic strategies are being explored:

Direct RAB35 Modulators

Activators:

Screen for compounds that promote RAB35-GTP binding
GEF mimetics to increase RAB35 activation
Challenge: Achieving specificity

Inhibitors:

GAP mimetics to accelerate RAB35 inactivation
Effector interaction blockers
Potential use in conditions with RAB35 gain-of-function

Indirect Modulation

Upstream regulators:

GEF inhibitors/activators
GAP inhibitors/activators
GDI modulators

Downstream effectors:

MICAL-1 inhibitors
OCRL modulators
FYCO1 modulators

Gene Therapy Approaches

viral vector delivery:

AAV9 preferentially targets neurons
Can deliver wild-type RAB35 or dominant-negative mutants
miRNA-based knockdown for gain-of-function variants

CRISPR editing:

Correct pathogenic RAB35 variants
Introduce protective polymorphisms
Modulate expression levels

Biomarker Development

Fluid Biomarkers

RAB35 levels in cerebrospinal fluid (CSF)
CSF autoantibodies against RAB35
Urinary RAB35 in certain conditions

Imaging Biomarkers

PET ligands for RAB35-rich regions
MRI-based approaches (limited)
Future: Specialized tracers

Clinical Biomarkers

Motor function scales
Cognitive assessments
Neuroimaging endpoints

Future Research Directions

Basic Science Priorities

Structure-function studies: High-resolution structure of RAB35-effectors complexes

Neuronal subtype specificity: RAB35 function in different neuron types

Temporal regulation: How RAB35 changes during aging

Compensatory mechanisms: Redundancy with other RAB GTPases

Translational Priorities

Target validation: Confirm RAB35 as viable therapeutic target

Biomarker development: Identify clinically useful biomarkers

Delivery optimization: Improve brain penetration of therapeutics

Patient stratification: Identify patients most likely to benefit

Clinical Priorities

Natural history studies: Understand RAB35-related disease progression

Outcome measures: Develop sensitive clinical endpoints

Trial design: Establish efficient clinical trial frameworks

Pathway Diagram

The following diagram shows the key molecular relationships involving RAB35 — Ras-Associated Protein 35 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

RAB35

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-rab35
kg_node_id	RAB35
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6494b45b81f5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-rab35'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

70%

Debates

0

Incoming

14

Outgoing

26

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

RAB35 — Ras-Associated Protein 35

RAB35 — Ras-Associated Protein 35

Overview

Pathway Diagram

RAB35 — Ras-Associated Protein 35

Overview

Pathway Diagram

Normal Biological Function

Regulation of Synaptic Vesicle Endocytosis

Actin Cytoskeleton Regulation

Endosomal Trafficking

Expression Pattern

Role in Neurodegenerative Diseases

Parkinson's Disease

Alzheimer's Disease

Other Neurodegenerative Conditions

Therapeutic Implications

Small Molecule Modulators

Gene Therapy Approaches

Target Validation Studies

Interacting Proteins and Pathways

Upstream Regulators

Effector Proteins

Related Pathways

Genetic Associations

GWAS Loci

Pathogenic Mutations

Research Gaps and Future Directions

Preclinical and Clinical Evidence

Comparison with Other RAB GTPases in Neurodegeneration

See Also

External Resources

References

Extended Analysis: RAB35 in Neuronal Physiology

Molecular Mechanisms of RAB35 Function

GTP/GDP Cycling

Effector Protein Interactions

RAB35 in Synaptic Transmission

Synaptic Vesicle Cycle Overview

RAB35 in Neurodevelopment

Axon Guidance

Neuronal Migration

Synapse Formation

RAB35 and Protein Quality Control

Autophagy

ER-associated Degradation (ERAD)

RAB35 in Glial Cells

RAB35 Post-Translational Modifications

RAB35 Polymorphisms and Human Disease

Parkinson's Disease GWAS Signals

Neurodevelopmental Disorders

Therapeutic Targeting Strategies

Direct RAB35 Modulators

Indirect Modulation

Gene Therapy Approaches

Biomarker Development

Fluid Biomarkers

Imaging Biomarkers

Clinical Biomarkers

Future Research Directions

Basic Science Priorities

Translational Priorities

Clinical Priorities

Pathway Diagram

💬 Discussion